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Abstract
Background: MicroRNAs (miRNAs) constitute a class of small non-coding RNAs that post-transcriptionally regulate
genes involved in several key biological processes and thus are involved in various diseases, including cancer. In
this study we aimed to identify a miRNA expression signature that could be used to separate between normal and
malignant prostate tissues.
Results: Nine miRNAs were found to be differentially expressed (p <0.00001). With the exception of two samples,
this expression signature could be used to separate between the normal and malignant tissues. A cross-validation
procedure confirmed the generality of this expression signature. We also identified 16 miRNAs that possibly could
be used as a complement to current methods for grading of prostate tumor tissues.
Conclusions: We found an expression signature based on nine differentially expressed miRNAs that with high
accuracy (85%) could classify the normal and malignant prostate tissues in patients from the Swedish Watchful
Waiting cohort. The results show that there are significant differences in miRNA expression between normal and
malignant prostate tissue, indicating that these small RNA molecules might be important in the biogenesis of
prostate cancer and potentially useful for clinical diagnosis of the disease.
Background
Prostate cancer is the most common type of cancer in
men and accounted for 36% of all male cancer cases in
Sweden during 2009. This type of cancer is a heteroge-
neous disease where some men have an aggressive lapse,
while others have a slower development [1]. During the
last years, prostate specific antigen (PSA) has been used
as a biological marker for this disease. However, since
the false positive rate for PSA values is very high, there
is an urgent need for new and improved markers [2].
The first microRNA (miRNA) was discovered in 1993
by Ambros and colleagues while they were performing a
genetic screen in Caenorhabditis elegans. They identified
a gene, later named lin-4, which does not code for a
protein but rather for a 22 nucleotide long RNA mole-
cule. It was shown that the function of this small RNA
is to repress the expression of the mRNA lin-14,b y
binding to the 3’UTR of the gene [3]. Later it was
discovered that miRNAs is a class of small RNAs (18-24
nt), that regulate gene expression post-transcriptionally
and they have been found in plants, animals and DNA
viruses [4-9]. MicroRNAs play a key role in the regula-
tion of genes involved a diverse range of biological pro-
cesses including development, cell proliferation,
differentiation and apoptosis [10,11]. Approximately
1048 human miRNAs have been identified to date (miR-
Base release 16) [12] and it is believed that miRNAs reg-
ulate about 30% of all protein coding human genes
[13,14].
Since many miRNAs are differentially expressed
between normal and malignant tissues, as shown in e.g.
breast and pancreatic cancer, miRNA expression profiles
have potential as tools for diagnosis and prognosis of
cancer [15-20]. It has been shown that expression pro-
files of miRNAs could be used to classify and correctly
diagnose even poorly differentiated tumor samples with
higher accuracy than mRNAs. Lu et al., investigated
tumors with histologically uncertain cellular origin for
which a clinical diagnosis was established by anatomical
context (colon, ovary, lung, breast and diffuse large B
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profiles could classify 12 out of 17 samples correctly
while, when using mRNA expression, only one out of 17
samples was correctly classified. In addition, biomarker
sets consisting of just a few miRNAs were informative
enough to differentiate between tissue types [16].
Several attempts to find a miRNA expression profile
for prostate cancer has been made during the last years
but the results have been inconclusive. At present there
are many conflicting results in the literature where
results often segregate between different data sets,
which can be due to study design, sample collection
methods or the sensitivity and specificity of the different
platforms used. Even though the results are conflicting,
s e v e r a ls t u d i e si n d i c a t et h a ti ti sp o s s i b l et of i n da
miRNA expression signature that can separate between
normal and malignant prostate tissues [19,21-26].
In this study we aimed to identify a diagnostic miRNA
expression signature, i.e. a set of miRNAs with expres-
sion profiles that consistently differ between normal and
malignant prostate tissues. If such an expression signa-
ture can be identified and shown to have high classifica-
tion accuracy, then it can potentially serve as the basis
for a future diagnostic tool for prostate cancer.
Results
In this study we included malignant prostate tissue and
adjacent normal prostate tissue from twenty patients of
the Swedish Watchful Waiting cohort, which consists of
men with localized prostate cancer diagnosed by trans-
urethral resection of the prostate (Table 1). The expres-
sion of 667 unique miRNAs was analyzed using the
TaqMan
® MicroRNA Array Set v2.0 from Applied Bio-
systems and miRNAs that were differentially expressed
between the malignant and adjacent normal prostate tis-
sues were identified by a paired Student’s t-test. In total,
30 miRNAs were found to be differentially expressed at
the 0.0001 significance level. When a more stringent p-
value of 0.00001 was applied, a subset of nine differen-
tially expressed miRNAs was identified. When the Ben-
jamini-Hochberg correction was performed on the p-
values, the differential expression of all the nine miR-
NAs was still significant at the p <0.001 level (Table 2).
Hierarchical clustering of the two sets of differentially
expressed miRNAs was performed, showing that both
these miRNA expression signatures could be used to
separate between the normal and malignant prostate tis-
sues, with the exception of three and two misplaced
samples, respectively (Figure 1, Figure 2). The PCA ana-
lysis performed on the smaller expression signature,
including nine miRNAs, confirmed the results from the
hierarchical clustering (Figure 3).
A PCA analysis of all 667 unique miRNAs was per-
formed to find subgroups among the 19 malignant
samples included in the analyses. By gradually decreas-
ing the p-value until groups emerged, we found a
threshold value (p <0.017) that could be used to identify
a set of 16 miRNAs, which arranged the samples into
four groups. We then evaluated these groups for corre-
spondence with Gleason scores and found that, with the
exception of three samples, the groups represented the
four Gleason scores included in the study (Figure 4).
To analyze whether the clear separation between the
normal and malignant tissues was due to the fact that
the same sample set was used for deriving the expres-
sion signature and for testing its performance, we per-
formed a generalization test using cross-validation. We
randomly chose 28 samples (14 malignant and the 14
corresponding normal samples) and used them for iden-
tification of differentially expressed miRNAs (p <0.0001).
The expression signature of these miRNAs was then
used to cluster the remaining 10 samples. This selection
and clustering procedure was repeated 15 times (15-fold
cross-validation). In each repetition we evaluated the
hierarchical clustering by setting a threshold resulting in
three clusters, since we had one outlier in many of the
clusterings. A perfect separation between the normal
and malignant tissues was found in four of the repeti-
tions. In four cases, one sample was misplaced (error
rate 10%), which means that one normal sample was
placed in a cluster where the majority of samples were
Table 1 Patient material
Sample Age Gleason score % WHO
1 80 7 20 2
2 84 6 15 2
3 79 6 60 2
4 83 7 60 2
5 83 6 15 1
67 4 6 5 2
78 6 6 2 3
8 69 7 60 2
9 85 6 10 2
10 78 7 20 2
11 76 8 70 3
12 73 7 80 2
13 75 10 40 3
14 71 9 20 2
15 74 7 15 3
16 79 10 40 3
17 71 9 60 3
18 78 9 60 3
19 85 7 20 3
20 91 9 80 3
Sample stands for the code of the patient (ranging from 1 to 20) and the
Gleason score is the total Gleason score from two different tumor areas in the
same patient. WHO shows the tumor grading according to the WHO
classification scale and % the percentage of tumor tissue.
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were misplaced, in three cases, three samples were mis-
placed, and in one case, four samples were misplaced
(Figure 5). Thus, the average error rate was 15%. We
also analyzed how many times the nine most significant
miRNAs were identified as differentially expressed in
the 15 repetitions of the generalization test, and found
that this number ranged from four to 13 (Table 2). A
permutation test was also performed, where the cross-
validation procedure was repeated with randomly per-
muted class labels, but this did not produce any mean-
ingful clusterings that could be interpreted in terms of
classification accuracy.
Discussion
In the present study, we aimed to find miRNAs with
expression profiles that consistently differ between nor-
mal and malignant prostate tissues. We randomly
selected 20 cases from the well-defined Swedish Watch-
ful Waiting cohort (Table 1) and investigated the
miRNA expression in malignant and the adjacent nor-
mal tissue in each individual in order to get a matched
control for each case. 19 samples were used in the sub-
sequent analyses since one sample had to be excluded
due to a technical error in handling the qPCR data.
Differentially expressed miRNAs were detected by
applying a paired Student’s t-test. The test revealed that
30 miRNAs were differentially expressed at a p < 0.0001
significance level and nine miRNAs at a more stringent
level (p < 0.00001). When a paired Wilcoxon test was
applied to the data, 18 miRNAs were identified as differ-
entially expressed (p < 0.0001) between the normal and
malignant samples. All except five of these miRNAs
were also detected as differentially expressed by the
paired Student’s t-test and seven of the most differen-
tially expressed from the t-test were also detected as dif-
ferentially expressed by the Wilcoxon test (See
Additional file 1). Due to the largely overlapping results,
we decided to proceed with the results from the t-test
under the assumption that the data used in the study is
approximately normally distributed.
The two sets consisting of nine and 30 differentially
expressed miRNAs were further analyzed in order to
find out if they could be used as expression signatures
to correctly separate between the normal and malignant
tissues. Hierarchical clustering was performed on the
larger expression signature, including 30 miRNAs, and
the analysis revealed that 16 out of 19 malignant sam-
ples were correctly classified, as well as all of the normal
samples (Figure 1). The hierarchical clustering analysis
was also applied for the smaller expression signature
consisting of nine miRNAs. Using this expression signa-
ture, 18 of the 19 malignant samples and 18 of the 19
normal samples were correctly classified. The reason for
one of the malignant samples being misclassified was
probably that it belongs to a low grade tumor (Gleason
score of 6). Its miRNA expression pattern may therefore
be more similar to normal tissues than to the fully
transformed malignant tumors with a higher Gleason
scores. However, all other GS 6 malignant samples were
correctly classified. The malignant sample that was
Table 2 Differentially expressed miRNAs
miRNA +/- p-value Reported no. of
times
Adjusted p-
value
MIR126* - 7.68e-
07
11 4.50e-04
MIR34A* - 1.19e-
06
13 6.09e-04
MIR622 + 1.52e-
06
9 3.88e-04
MIR195 - 3.06e-
06
7 8.55e-04
MIR26A - 4.05e-
06
6 4.50e-04
MIR30D + 4.35e-
06
9 4.50e-04
MIR29A* - 4.48e-
06
4 6.09e-04
MIR425* + 5.65e-
06
6 4.50e-04
MIR342-3P + 6.11e-
06
4 6.09e-04
MIR345 - 1.07e-05 2 1.77e-03
MIR24 - 1.08e-05 3 6.09e-04
MIR484 - 1.12e-05 2 1.16e-03
MIR497 + 1.13e-05 4 6.09e-04
MIR30E + 1.22e-05 3 6.09e-04
MIR93 + 1.29e-05 3 1.64e-03
MIR221* - 1.37e-05 1 1.64e-03
MIR774 + 1.44e-05 2 1.64e-04
MIR152 - 2.34e-05 0 1.37e-03
MIR27B - 2.47e-05 4 8.62e-04
MIR101* + 3.34e-05 2 4.69e-04
MIR145* - 3.51e-05 1 4.69e-04
MIR143 - 4.65e-05 1 1.40e-03
MIR100 - 5.12e-05 1 6.09e-04
MIR519B-
3P
+ 5.12e-05 2 1.40e-03
MIR200C* + 6.66e-05 1 3.88e-04
MIR501-5P + 6.80e-05 0 1.12e-03
MIR200C + 6.84e-05 2 3.88e-04
MIR30A + 6.84e-05 0 1.64e-03
MIR191 + 7.85e-05 1 6.09e-04
MIR30B - 9.43e-05 1 2.06e-03
MicroRNAs differentially expressed between normal and malignant tissue
samples of the prostate with p< 0.0001. The nine miRNAs in bold text were
also significant at the 0.00001 level. The signs +/- indicate if the miRNAs were
up- or down-regulated in the malignant tissue compared to the adjacent
normal prostate tissue. The reported number of times stands for the number
of repetitions in which the miRNA was reported as differentially expressed in
the 15-fold cross-validation test.
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Page 3 of 10misclassified had a low percentage of tumor cells (5%),
which also might explain why it was placed in the nor-
mal cluster. On the other hand, the sample containing
only 2% of tumor cells (7M) was correctly classified
within the malignant cluster, which may indicate in
some cases, the expression signature also works for tis-
sues with a low percentage of tumor cells. A normal
sample was also misclassified (20N), and we hypothesize
that this might be due to that the normal tissue sur-
rounding the tumor area might have been affected by
the tumor, a phenomena called TINT (tumor indicating
normal tissue) that has begun to be discussed within the
prostate cancer area recently [27]. The PCA analysis of
the nine differentially expressed miRNAs confirmed the
results from the clustering analysis, as the same samples
(6M and 20N) were misclassified using this test (Figure
2, Figure 3).
A miRNA expression signature that will be used for
clinical purposes should include a limited number of
miRNAs due to practical and economic reasons. Thus,
in addition to our initial s e to f3 0d i f f e r e n t i a l l y
expressed miRNAs we also analyzed a reduced expres-
s i o ns i g n a t u r ei n c l u d i n gt h en i n em o s td i f f e r e n t i a l l y
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Min = 0.00      20.27  Max = 40.53 
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Figure 1 miRNA expression signature consisting of 30 differentially expressed miRNAs. Differentially expressed miRNAs (p <0.0001) were
clustered and the results show that the expression profiles of these 30 miRNAs could be used to separate the normal (N) from the malignant
(M) tissue samples with the exception for three malignant samples (6M, 8M and 20M).
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Page 4 of 10expression signature could classify normal and malig-
nant samples more correctly than the larger signature,
which is probably due to the more stringent approach
when detecting differentially expressed miRNAs (a lower
p-value).
Six of the miRNAs (MIR26A, MIR126*, MIR195,
MIR30D, MIR29A* and MIR342-3P) included in the
smaller expression signature, have previously been
described to be involved in the development of prostate
cancer [19,22-25,28,29]. The expression of MIR126* has
been investigated in prostate cancer in two previous stu-
dies and the results from these studies correspond well
with our results as the miRNA was downregulated in
both studies [23,29]. Porkka et al.,i n v e s t i g a t e dt h e
expression of three of the miRNAs included in our
expression profile, MIR195, MIR26A and MIR29A* [22].
Their results correspond well with the results from our
study since we found that all these three miRNAs were
downregulated in malignant prostate tissues. MIR26A
and MIR30D have also been shown to be downregulated
in malignant prostate tissue in a another study [24]
while in two other studies MIR26A together with
MIR195 were found to be upregulated in malignant
prostate tissues [19,25]. The results from the previous
studies validate our results that MIR126*, MIR195,
MIR26A, MIR29A* and MIR30D are differentially
expressed in prostate cancer.
Three of the miRNAs in the signature (MIR26A,
MIR126* and MIR34A*) have experimentally validated
target genes (Table 3). SLC45A3,at a r g e tg e n eo f
MIR126* encodes a prostate specific antigen called pros-
tein [29]. There are five validated target genes of
MIR26A, SMAD1, PLAG1, TGFBR2, SERBP1 and EZH2,
and one validated target gene, NOTCH1, of MIR34A*
[19,30-35]. These target genes are involved in pathways
related to e.g. cell growth and proliferation. None of the
miRNAs in the small expression signature seems to be
prostate specific and many of them are differentially
expressed in several other diseases, such as lung cancer
and leukemias [36-41], which indicates that these miR-
NAs might be important in general cancer development.
This means that the expression profile from a single
miRNA within this nine miRNA expression signature
may not be reliable for diagnosis of prostate cancer spe-
cifically. However, the combination of the expression
profiles of all nine miRNAs could potentially be prostate
specific and thus be used for diagnostic purposes, even
in cases where prostate samples are replaced by other
cell types, for example circulating tumor cells [42,43].
In order to test the generality of the expression signa-
ture, we randomly chose 28 samples (14 malignant and
the 14 corresponding normal tissues) to find a new set
of differentially expressed miRNAs, which was then
used to cluster the remaining 10 samples. When
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Figure 2 miRNA expression signature consisting of nine differentially expressed miRNAs. Differentially expressed miRNAs (p <0.00001)
were clustered and the results show that the expression profiles of these nine miRNAs could be used to separate between the normal (N) and
malignant (M) tissue samples with the exception of one normal sample (20N) and one malignant sample (6M).
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Page 5 of 10repeated 15 times, this analysis indicated that regardless
of the selection of 28 randomly chosen samples, at least
one of the nine most differentially expressed miRNAs
from our first analysis was identified as differentially
expressed (Table 2). We also analyzed how many times
each of the nine differentially expressed miRNAs in our
signature were chosen as differentially expressed within
this analysis (Table 2). We saw that MIR34A* and
MIR126* followed by MIR622 and MIR30D are the
miRNAs that are differentially expressed in most of the
repetitions performed (87%, 73%, 60% and 60% of the
repetitions, respectively).
No clear tendencies for how different Gleason scores
cluster together were found in the hierarchical clustering
analysis when using the set of nine miRNAs. We therefore
performed a PCA analysis of all 667 miRNAs to find sub-
groups within the malignant samples. The result from this
analysis was a set of 16 miRNAs that could be used to
Figure 4 Principal component analysis to find subgroups
within the malignant samples. A set of 16 miRNAs could be used
to separate the malignant samples according to Gleason scores (GS)
with the exception of three samples: one GS 6 sample placed in the
GS 7 group, one GS 7 sample placed in the GS 6 group, and one
GS 7 sample placed in the GS 9 group. In the figure, one GS 7
sample is hidden behind another GS 7 sample. The strings between
samples correspond to their nearest neighbors. Blue: GS 6, green:
GS 7, yellow: GS 9, white: GS 10.
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Figure 5 Number of misclassified samples in cross-validation
procedure. Number of misclassified samples in each of the 15
repetitions performed in the generalization test. The error rate of
the clusterings range from 0 to 40%, with an average error rate of
15.3%, meaning that on average, 1.5 of the 10 test samples was
placed in a cluster where the majority of the samples belonged to
the opposite class (malignant or normal).
Figure 3 Principal component analysis of the nine miRNA
expression signature. Principal component analysis of the nine
miRNAs differentially expressed at the 0.00001 significance level.
Only two samples (20N and 6M) were misplaced. The percentages
on the axes describe the amount of variance that is picked up by
the principal components in that direction. Green: malignant tissue
sample, red: normal tissue sample.
Table 3 Validated target genes
miRNA Validated target genes
MIR126* SLC45A3 [29]
MIR34A* NOTCH1 [35]
MIR622 -
MIR195 -
MIR26A SERBP1,SMAD1,PLAG1,TGFBR2,EZH2 [19,30-34]
MIR30D -
MIR29A* -
MIR425* -
MIR342-3P -
Validated target genes for the nine most significantly differentially expressed
miRNAs. Only three of the miRNAs currently have validated target genes.
- No validated target genes
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Page 6 of 10classify the samples into four subgroups, which largely
corresponded with Gleason scores, since only three of the
19 samples were misplaced. These results indicate that it
may be possible to find a miRNA expression signature
that can be used to aid tumor classification according to
Gleason scores, which could be a useful complement to
the manual classification performed by pathologists today.
To obtain a more certain result regarding the correspon-
dence between miRNA expression signatures and Gleason
score, a more thorough study needs to be performed,
focusing on this relationship.
Conclusions
To conclude, we have shown that a miRNA expression
signature consisting of nine miRNAs could separate
between the normal and malignant prostate tissues with
high accuracy. This separation seems to be achievable
also on unseen samples, since a cross-validation test was
performed and yielded similar results (85% of samples
correctly classified). We have also showed that sub-
groups in the malignant data, revealed by miRNA
expression profiles, show high concordance with Glea-
son scores. The miRNA signature proposed in this study
needs to be evaluated in a larger patient material and
preferably with another method, such as in situ hybridi-
zation. The results show that there are significant differ-
ences in miRNA expression between normal and
malignant prostate, indicating that these small RNA
molecules might be important in the biogenesis of pros-
tate cancer and potentially also useful for clinical diag-
nosis of the disease.
Methods
Patient material
Patients were recruited from the population-based
Swedish Watchful Waiting cohort [44], consisting of
1256 men with localized prostate cancer. These men
had symptoms of benign prostatic hyperplasia (lower
urinary tract symptoms) and were subsequently diag-
nosed with prostate cancer through transurethral resec-
tion (TUR-P). All men in this study were determined at
the time of diagnosis to have clinical stage T1a or T1b,
Mx, and Nx (small tumor, no metastases and no lymph
node involvement), according to the staging system of
the 2002 American Joint Committee on Cancer, called
Classification of Malignant Tumors (TNM) [45]. The
prospective follow-up time of this cohort is now up to
30 years. This study includes samples from men who
were diagnosed at the University Hospital in Örebro
(1977-1991) and at four centers in the southeast region
of Sweden: Kalmar, Norrköping, Linköping, and Jönköp-
ing (1987-1999). The study was approved by the ethical
committee in the Uppsala-Örebro region (Application
number M58-05). The material consisted of formalin
fixed paraffin embedded (FFPE) malignant prostate tis-
sues from 20 cases and the adjacent normal tissue from
each case, i.e. in total 40 paired samples. We collected
cases randomly within each category of Gleason score
(6-10) to get an equal distribution of histological differ-
entiation between low grade (6-7) and high grade (8-10)
Gleason scores. In addition, the tumor material con-
sisted of different percentages of tumor cells in order to
reflect the clinical reality (Table 1).
MicroRNA qPCR arrays
The TaqMan
® MicroRNA Array Set v2.0 from Applied
Biosystems was used in this study (Applied Biosystems,
Foster City, CA, USA). It consists of two cards (Card
A and Card B) containing 364 TaqMan
® MicroRNA
assays plus 20 control assays per card, which enables
quantification of 667 unique human miRNAs in total.
Card A contains miRNAs that tend to be functionally
defined, and are broadly and/or highly expressed. The
miRNAs in card B are narrowly expressed and/or
expressed at low levels and are usually not functionally
defined.
RNA extraction and cDNA preparation
Malignant and adjacent normal tissue areas on the par-
affin blocks were marked by a pathologist prior to
punching out 3-4 cores (ø 0.6 mm) using the Tissue
Micro Array equipment (Pathology devices, Westmin-
ster, USA). The Recover All Total Nucleic Acid Isola-
tion Kit optimized for FFPE samples (Ambion, Foster
City, CA, USA) was used to extract total RNA. A
reverse transcription reaction of 4-10 ng of total RNA
was performed using the TaqMan
® MicroRNA reverse
transcription kit and Megaplex
™ RT primers, human
pool v2.0 (Applied Biosystems). Subsequently, the cDNA
samples were pre-amplified using Megaplex
™ PreAmp
primers and TaqMan
® Preamp master mix (Applied
Biosystems).
Quantitative PCR
The pre-amplified cDNA samples were diluted in a 0.1
X TE Buffer (pH 8.0) before use in the qPCR reaction.
The diluted pre-amplified cDNA was mixed with Taq-
Man
® PCR master mix II (No AmpErase UNG, Applied
Biosystems) and run in a 40 cycle qPCR reaction on the
TaqMan
® MicroRNA A and B Cards. All reactions were
performed on the Applied Biosystems 7900 HT system.
Data analysis
Raw Ct-values (Cycle threshold, i.e. the number of
cycles where the amount of amplified cDNA crosses a
defined threshold) were calculated using the SDS
Carlsson et al. Cancer Cell International 2011, 11:14
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Page 7 of 10software (Applied Biosystems), applying manually
selected thresholds for each miRNA (see Additional file
2). Due to a technical error in the handling of qPCR
data, one sample (sample 11) had to be excluded from
further analyses.
All statistical analyses were performed in the program-
ming software R [46]. The raw Ct values were normal-
ized using qPCRNorm quantile normalization, which is
a data-driven normalization strategy for high-throughput
qPCR data [47]. To select miRNAs to be included in the
expression signature, differentially expressed miRNAs
were detected by applying a paired Student’st - t e s to n
the normalized data (p <0.0001 and p <0.00001) and a
Benjamini Hochberg multiple testing correction
(included in the multtest R package) was applied to the
p-values. A paired Wilcoxon test was also applied for
comparison (see Additional file 1).
To test the accuracy of the miRNA expression signa-
tures, hierarchical clustering analysis was performed on
the differentially expressed miRNAs using the Permut-
Matrix clustering tool [48]. For measurement of similar-
ity between expression profiles, Euclidean distance was
applied. Clustering was done using the average linkage
rule, which means that the distance between two clusters
is represented by the average of all pairwise distances
between the objects contained in the two clusters.
To analyze the generality of the miRNA expression
signature, the following cross-validation test of generali-
zation was applied. A set of 14 paired samples (malig-
nant and normal from the same case) was randomly
selected and a new classification signature generated by
identifying the differentially expressed miRNAs on these
28 samples using a paired Student’st - t e s t( p <0.0001).
The remaining 10 samples (five normal and five malig-
nant) were then clustered based on the expression
values of the selected miRNAs, and the separation
between normal and malignant samples was recorded.
This procedure was repeated 15 times and the average
classification accuracy of the 15 clusterings was calcu-
lated (Figure 6).
A principal component analysis (PCA) was performed
on the miRNA expression signatures, using Omics
Explorer, Version 2.0 Beta (Qlucore AB, Lund, Sweden),
to confirm the results from the hierarchical clusterings.
An unsupervised PCA analysis was also performed to
find subgroups within the malignant tissues. In this ana-
lysis, all miRNAs were initially used and the p-value was
gradually decreased until subgroups within the data
were revealed. These groups were then evaluated for
correspondence with the ap r i o r iknown groups, i.e.
normal versus malignant and the different Gleason
scores.
Figure 6 Cross-validation procedure. Overview over the cross-validation procedure performed to test the generality of the clustering results.
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Additional file 2: microRNA qPCR array raw data. Raw data from
microRNA qPCR card A and B (XLS-format).
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